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Abstract 
BACKGROUND: Traumatic brain injury (TBI) exerts a significant impact on society with regards to physical, 
affective, and cognitive impairment. The consequent cognitive sequelae include a problem in memory, attention, 
concentration, and processing speed. Following traumatic brain injury, inflammatory response developed, 
characterised by increased interleukin 1-β (IL-1β) levels in the blood. IL 1-β at pathophysiological concentration 
has been reported to cause an inhibition of the expression of long-term potentiation (LTP) in the areas CA1, CA3, 
and dentate gyrus of the hippocampus.  
AIM: This study aims to determine whether high IL-1β serum is a predictor of decreased cognitive function in mild 
TBI. 
METHODS: This is a prospective cohort study conducted at the emergency room, surgical and neurologic ward at 
Sanglah Hospital from November 2017 until January 2018. As many as thirty-five mild TBI with normal IL-1β 
serum (< 0.0565 pg/ml) and thirty-five of those with high IL-1β serum (≥ 0.0565 pg/ml) subjects were included 
within the corresponding period. The decrease of cognition after trauma was measured seven days later.  
RESULTS: This study demonstrated that group with high IL-1β serum levels were at higher risk of suffering from 
cognitive impairment after TBI when compared with the group with normal IL-1β serum levels (RR = 2.6; 95% CI 
1.49-4.55, p < 0.001). 
CONCLUSION: Mild TBI with high serum IL-1β levels were more than twice likely to experience decreased 
cognitive function than those with normal IL-1β levels. 
 
 
 
 
 
 
 
 
Introduction 
 
Traumatic brain injury (TBI) is a neuro-
emergency situation which has a significant primary 
impact (i.e. cost of treatment) and also secondary 
impact (i.e. loss of productivity) in the patient. There 
are various TBI complications including physical, 
affective, and cognitive impairment. Furthermore, 
cognitive impairment comprises memory dysfunction, 
poor concentration and thinking process [1]. 
Meanwhile, physical impairment may occur as a 
headache, dizziness, and lethargy, whereas affective 
impairment includes emotional disturbance such as 
irritability, anxiety disorder, and depression. Those 
impairments may potentially affect the ability of 
patients to do work as usual and their role in society 
[2]. TBI is the third leading cause of death related to 
traumatic cases in the U.S.; it is estimated that 1.7 
million American citizens suffered from TBI every year 
[3].  
The resulting inflammatory response after TBI 
occurs both locally at the injured area (so-called 
neuroinflammation) and systemically. After the initial 
injury, complement is activated which subsequently 
followed by neutrophil, lymphocyte, and monocyte 
infiltration via blood-brain barrier. Also, secretion of 
pro-inflammatory cytokines and mediators, 
prostaglandin, reactive agents, and other 
inflammatory molecules also occur simultaneously. 
These processes subsequently lead to increased 
chemokine and adhesion molecule expressions, 
enabling immune cells and microglia to infiltrate brain 
parenchyma which initiates secondary brain injury [4] 
[5].  
Interleukin 1-β (IL-1β) is an inflammatory 
marker that can be potentially used as a predictor of 
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TBI. IL-1β is produced by the central nervous system 
as a response to several stimuli, such as 
administration of peripheral lipopolysaccharides, TBI, 
acute stress, anorexia, and administration of β-α 
adreno-receptor agonists. In the brain, IL-1β levels are 
particularly high in the hippocampus and hypothalamic 
area. High IL-1β levels to the extent of its 
pathophysiologic concentration (0.1-10 ng/mL) as 
found in post-mortem tissue and cerebrospinal fluid in 
a chronic disease like Alzheimer have been reported 
to inhibit long-term potentiation (LTP) in CA1, CA3, 
and dentate gyrus of the hippocampal area [6].  
 A study conducted by Coogan et al., [6] also 
found that chronic high IL-1β levels were found to 
inhibit LTP induction process. Furthermore, another 
study by Ross et al., [7] concluded that IL-1β at 1 and 
10 ng/mL could decrease the post-synaptic excitatory 
potential by 25% in CA1 area of the rat hippocampus. 
However, further studies are required to profile IL-1β 
levels increment if it is to be used as a predictor of 
cognitive function in TBI.  
Therefore, this study aims to determine 
whether high IL-1β serum is a predictor of decreased 
cognitive function in mild TBI. 
 
 
Material and Methods 
 
This was an analytic observational 
prospective cohort study, with consecutive non-
random sampling method. This study had been 
approved by the Ethical Committee for Human Study, 
Faculty of Medicine, Udayana University and all of the 
investigators had ensured that the study adhered to 
the WMA Declaration of Helsinki [8]. Also, every 
patient who participated in this study had agreed and 
signed informed consent paper. 
This study was conducted at the emergency 
room, surgical and neurologic ward at Sanglah 
Hospital from November 2017 until January 2018. 
During the corresponding period, as many as thirty-
five subjects suffering from mild TBI with normal IL-1β 
serum (< 0.0565 pg/mL) and thirty-five mild TBI 
subjects with high IL-1β serum (≥ 0.0565 pg/mL) were 
included. 
The cognitive state examination pre-TBI, 
depression, and cognitive evaluation post-TBI were 
done using Short Form of the Informant Questionnaire 
on Cognitive Decline in the Elderly (Short IQCODE), 
Hamilton Rating Scale for Depression, and Indonesian 
Version of Montreal Cognitive Assessment (MoCA-
INA) questionnaire, respectively. Mild TBI was 
diagnosed based on the subject’s history, physical 
and neurological examinations and confirmed by non-
contrast CT scan. IL-1β levels were measured during 
admission, i.e. at the onset of initial brain injury, 
before 24 hours using ELISA-based Quantikine HS 
Human IL-1/beta-1F2 Immunoassay (R&D system, 
USA). The protocol was conducted according to the 
procedure written at the packaging.  
The collected data were subsequently 
analysed using IBM SPSS version 20 for Windows 
(IBM Inc, USA). Data were analysed in two phases, 
i.e. descriptive and analytical phases. Analytical 
statistics were performed in order to obtain the relative 
risk of cognitive impairment incidence post mild TBI 
between two groups, along with test for significance 
using Chi-square test. P value of < 0.05 was 
considered significant with confidence interval of 95%. 
 
 
Results 
 
70 subjects were involved in this study, whom 
further divided into two groups (normal vs. high IL-1β), 
each with 35 subjects. IL-1β serum levels from all 
subjects were within 0.028 to 2.315 pg/mL. An ROC 
curve was then determined in order to define the 
ability of IL-1β serum levels as a predictive factor of 
cognitive impairment. The obtained AUC of 86.9% 
(95% CI 78.5%-95.3%, p < 0.001) was considered 
adequate statistically (Figure 1). The results of ROC 
coordinate had showed that IL-1 β cut-off point of > 
0.0565 pg/mL which was used in this study had a 
88.9% sensitivity and 64.7% specificity. 
 
Figure 1: ROC of IL-1β serum levels toward cognitive decline with 
86.9% AUC 
 
Accordingly, all subjects were divided into two 
groups, i.e. those with high IL-1β as defined by serum 
levels of > 0.0565 pg/mL and low IL-1β defined by 
serum levels of < 0.0565 pg/mL. 
The characteristics of subjects based on IL-1β 
levels were presented at the Table 1. 
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Table 1: Subject’s baseline characteristics 
Variables 
Normal IL-1β 
value 
High IL-1β value 
p 
n (%) n (%) 
Gender    
 Male 16 (45.7) 27 (77.1) 
0,007
a 
 Female 19 (54.3) 8 (22.9) 
Age   
 
1,000
a  17-25 years old 15 (42.9) 15 (42.9) 
 26-35 years old 20 (57.1) 20 (57.1) 
Education 
Middle School 
 
32 (91.4) 
 
32 (91.4) 
 
1,000
b 
Bachelor degree 3 (8.6) 3 (8.6) 
a
Chi-square test; 
b
Fisher’s Exact test. 
 
As many as 16 (45.7%) male and 19 female 
(54.3%) subjects had normal IL-1β levels, whereas 27 
male (77.1%) and 8 female (22.9%) subjects had high 
IL-1β serum levels. Within normal IL-1β group, 15 
(42.9%) subjects were of late adolescents and 20 
(57.1%) were of early adults, while in high IL-1β 
group, 15 (42.9%) subjects were of late adolescents 
category and 20 (57.1%) subjects were of early adults 
(p = 1). 
Similarly, education levels within group were 
alike, i.e. 32 (91.4%) vs. 32 (91.4%) subjects from 
normal and high IL-1β serum groups, respectively, 
graduated from middle school, whereas as many as 3 
(8.6%) subjects from both groups graduated from 
university. 
Table 2: Bivariate analysis of serum IL-1β levels with Cognitive 
Function 
Variables 
Cognitive Function 
RR (IK 95%) P Decreased 
n (%) 
Normal 
n (%) 
Serum IL-1β levels 
Normal 10 (28.6%) 25 (71.4%) 
2.60 (1.49-4.55) <0.001 
High 26 (74.3%) 9 (25.7%) 
 
The incidence of cognitive function 
impairment in mild TBI subjects with normal serum IL-
1β levels was 28.6%, significantly lower when 
compared with those of high serum IL-1β group 
(74.3%). Accordingly, subjects with high serum IL-β 
levels were more prone to suffer from the decreased 
cognitive function as opposed to a normal group (RR 
2.60; 95% CI 1.49-4.55, p < 0.001).  
Table 3: Bivariate analysis of other variables with cognitive 
function impairment 
Other Variables Cognitive Function 
RR 
(IK 95%) 
p  Decreased 
n (%) 
Normal 
n (%) 
Male 
Female 
26 (72.2) 
10 (27.8) 
17 (50.0) 
17 (50.0) 
1.63 
(0.94-2.82) 
0.056
a 
     
Late adolescent 
Early adult 
11 (30.6%) 
25 (69.4%) 
19 (55.9%) 
15 (44.1%) 
0.59 
(0.35-0.99) 
0.032
a 
     
Middle School 
Bachelor Degree 
33 (91.7%) 
3 (8.3%) 
31 (91.2%) 
3 (8.8%) 
1.03 
(0.45-2.38) 
1.000
b 
a
Chi-square Test; 
b
Fisher’s Exact Test. 
 
Further analyses revealed that decreased 
cognitive function was more commonly found among 
males (72.2%) across all groups. Indeed, males were 
more likely to suffer from decreased cognitive function 
than females, despite statistically non-significant (RR 
= 1.63; 95% CI 0.94-2.82, p = 0.056). In regards to 
age group, fewer late adolescent suffered from 
decreased cognitive function as opposed to early 
adult (30.6% vs. 69.4%, respectively; RR 0.59, 95% 
CI 0.35-0.99, p = 0.032). Furthermore, with respect to 
education levels, decreased cognitive function did not 
differ significantly in middle school- vs. university 
graduates (RR = 1.03, 95% CI 0.45-2.38, p = 1.00). 
 
 
Discussion 
 
This study showed that there were 27 males 
(77.1%) and 8 females (22.9%) who suffered from TBI 
had high serum IL-1β levels. These results were in 
accordance to a study conducted at Hasan Sadikin 
Hospital during the 2008-2010 period, in which as 
many as 79.8% males and 20.2% females from 3,578 
subjects suffered from TBI [9]. This significant 
proportional difference of sex-based TBI was not 
unfamiliar, as males ride 4.5 times more frequently 
than females and tend to engage in physical conflict, 
thus potentially result in head injuries [10].  
In normal serum IL-1β group, as many as 15 
subjects were of late adolescent (42.9%), and 20 
subjects were of early adult (57.1%). In this study, age 
was focused on these two groups since according to 
Indonesian national health statistics, TBI occurs most 
often among 15-44 years old age group. The 
decreased cognitive function was found more 
commonly among early adult with statistical 
significance. The result was apparently by another 
study which found that older subjects demonstrated a 
greater cognitive decline than younger one over a 5-
year period [11]. Herein, we demonstrated a higher 
incidence of an acute decrease in cognitive function in 
older individuals shortly after TBI. These results may 
in part be explained by the age-related difference in 
synaptic plasticity and cortical volume. It is still to be 
determined, however, if the cognitive decline persists 
over a longer period, and if there is any difference in 
the status and rate of meaningful cognitive recovery 
among different age groups. 
In both normal and high serum IL-1β groups, 
decreased cognitive function did not seem affected by 
educational level. This is contrary to the common 
belief and clinical findings that a higher educational 
level may be protective to cognitive decline post-TBI, 
with one of the most important factors is having higher 
cognitive reserve [12]. Our study results may be 
limited by the scarcity of subjects who had attained 
university degree (3 subjects in each group), thus 
providing inadequate power to the results.  
In this study, serum IL-1β levels among all 
subjects were within 0.028 pg/mL to 2.315 pg/mL. 
Furthermore, AUC derived from ROC method was 
86.9% (95% CI 78.5%-95.3%, p < 0.001). Statistically, 
AUC of 86.9% had an adequate diagnostic value 
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(Figure 1). ROC coordinate showed that IL-1β cut-off 
point of > 0.0565 pg/mL used in this study had 88.9% 
sensitivity and 64.7% specificity. In our study, IL-1β 
levels among all groups were markedly lower than 
previous studies. Several reasons might account for 
this discrepancy, i.e. firstly, we included relatively 
younger subjects (15-44 years old) as opposed to a 
study with a wide age range (18-74 years old) [13]. IL-
1β is not specific for TBI. Thus various diseases, 
including infection or metabolic/degenerative can 
obscure the result. Secondly, even when there are 
comorbidities, IL-1β levels can still surprisingly 
detected at minute levels, ranging from 0.5 pg/mL in 
the hip fracture to 1.39 pg/mL in subjects with 
congestive heart failure [14]. Given the wide variations 
of IL-1β levels, it should be ideally measured 
periodically and assessed for its elevation/decline 
rather than its absolute levels per se.  
Most importantly, this study found a markedly 
increased risk of experiencing decreased cognitive 
function among subjects with high IL-1β levels. Our 
study thus confirmed the previous findings, for 
instance, one which was conducted by Coogan et al., 
[6] that abnormally high IL-1β levels had been shown 
to inhibit LTP. IL-1β at 1 and 10 ng/mL can decrease 
the post-synaptic excitatory potential by 25% in CA1 
area of the rat hippocampus, thus potentially affecting 
memory formation, or even its storage and retrieval. 
In conclusion, mild TBI with high serum IL-1β 
levels was more than twice likely to experience 
decreased cognitive function than those with normal 
IL-1β levels. 
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